nach oben

Erschienen in:

01.04.2014 | Original Paper

Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer

verfasst von: Xiaoti Lin, Minqing Wu, Peng Liu, Fengqin Wei, Laisheng Li, Hailin Tang, Xinhua Xie, Xiaoping Liu, Lu Yang, Xiaoming Xie

Erschienen in: Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Expression of trans-activation-responsive-RNA-binding protein 2 (TARBP2) varied from normal cell lines to various cancer cell lines. The discussion of TARBP2 serve as tumor suppressor or tumor promotor goes on. However, its expression in breast cancer remains unknown. The aim of present study was to assess the expression of cytoplasm TARBP2 as potential prognostic marker in breast cancer. We further investigated cytoplasm TARBP2 could be a novel target in treatment for late-stage breast cancer and triple-negative breast cancer (TNBC). A total of patients with breast cancer were involved in our cohort. Immunohistochemical staining for TARBP2 on tissue microarray and western blot were used. Immunohistochemistry showed that cytoplasm TARBP2 was frequently up-regulated in breast carcinoma. This finding was in line with the result of western blot analysis. Further investigation showed that cytoplasm TARBP2 expression in non-TNBC was higher than that of their adjacent normal breast tissues (NBT), and TNBC was the highest of the three groups. The positive expression of cytoplasm TARBP2 in stage III breast cancer, stage I–II breast cancer, and NBT decreased gradually. In addition, univariate and multivariate survival analysis revealed cytoplasm TARBP2 was an independent prognostic factor for breast cancer. Breast cancer patients with cytoplasm TARBP2 expression had poorer disease-free survival and overall survival, and similar results were obtained in TNBC group and stage III breast cancer group. Our results provide convincing evidence for the first time that the expression of cytoplasm TARBP2 is up-regulated in breast cancer. Breast cancer patients with TARBP2 cytoplasm expression have unfavorable prognosis. Patients of TNBC and late-stage breast cancer with higher cytoplasm TARBP2 expression have an unfavorable prognosis.

Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.PubMedCrossRef

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRef

Autier P, Hery C, Haukka J, et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27(35):5919–23.PubMedCrossRef

Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.PubMedCrossRef

Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86.

Mahoney MC, Newell MS. Breast intervention: how i do it. Radiology. 2013;268(1):12–24.PubMedCrossRef

DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics 2011. CA Cancer J Clin. 2011;61(6):409–18.PubMedCrossRef

Lee E, McKean-Cowdin R, Ma HY, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29(33):4373–80.PubMedCentralPubMedCrossRef

Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852–8.PubMedCrossRef

10.

Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef

11.

Metzger O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879–87.CrossRef

12.

Devi BC, Tang TS, Corbex M. Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak. Malays Ann Oncol. 2007;18(7):1172–6.CrossRef

13.

Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, et al. Male breast cancer. Cancer Treat Rev. 2010;36(6):451–7.PubMedCrossRef

14.

Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27):4515–21.PubMedCentralPubMedCrossRef

15.

Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470–7.PubMedCentralPubMedCrossRef

16.

Benkirane M, Neuveut C, Chun RF, et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 1997;16(3):611–24.PubMedCentralPubMedCrossRef

17.

Gatignol A, Buckler-White A, Berkhout B, et al. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science. 1991;251(5001):1597–600.PubMedCrossRef

18.

Gatignol A, Duarte M, Daviet L, et al. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 1996;5(4–5):217–28.PubMed

19.

Bai S, Nunez AL, Wei S, et al. Microsatellite instability and TARBP2 mutation study in upper urinary tract urothelial carcinoma. Am J Clin Pathol. 2013;139(6):765–70.PubMedCrossRef

20.

De Vito C, Riggi N, Cornaz S, et al. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell. 2012;21(6):807–21.PubMedCrossRef

21.

Melo SA, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41(3):365–70.PubMedCrossRef

22.

Caramuta S, Lee L, Ozata DM, et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(4):551–64.PubMedCentralPubMedCrossRef

23.

Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA. 2011;108(11):4394–9.PubMedCentralPubMedCrossRef

24.

Fu X, Xue C, Huang Y, et al. The activity and expression of microRNAs in prostate cancers. Mol BioSyst. 2010;6(12):2561–72.PubMedCrossRef

25.

Sand M, Skrygan M, Georgas D, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012;350(1):119–26.PubMedCrossRef

26.

Sand M, Skrygan M, Georgas D, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2012;51(11):916–22.PubMedCrossRef

27.

Wu M, Wei W, Xiao X, et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012;29(5):3240–9.PubMedCrossRef

28.

Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641–7.PubMedCrossRef

29.

Stephan EA, Chung TH, Grant CS, et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther. 2008;7(2):425–31.PubMedCrossRef

30.

Bannwarth S, Talakoub L, Letourneur F, et al. Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line. J Biol Chem. 2001;276(52):48803–13.PubMedCrossRef

31.

Park H, Davies MV, Langland JO, et al. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci USA. 1994;91(11):4713–7.PubMedCentralPubMedCrossRef

32.

Francois C, Duverlie G, Rebouillat D, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 2000;74(12):5587–96.PubMedCentralPubMedCrossRef

33.

Liu H. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci. 2012;69(21):3587–99.PubMedCentralPubMedCrossRef

34.

Yu Z, Pestell RG. Small non-coding RNAs govern mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2012;17(1):59–64.PubMedCentralPubMedCrossRef

35.

Si ML, Zhu S, Wu H, Lu Z, et al. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–803.PubMedCrossRef

36.

Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28(4):341–7.PubMedCentralPubMedCrossRef

37.

Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.PubMedCrossRef

38.

Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67(22):11001–11.PubMedCrossRef

39.

Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010;141(7):1195–207.PubMedCrossRef

40.

Ibarra I, Erlich Y, Muthuswamy SK, et al. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev. 2007;21(24):3238–43.PubMedCentralPubMedCrossRef

41.

Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.PubMedCrossRef

42.

Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.PubMedCrossRef

43.

Lehmann U, Hasemeier B, Christgen M, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008;214(1):17–24.PubMedCrossRef

44.

Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.PubMedCrossRef

45.

Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194–204.PubMedCrossRef

46.

Li LS, Xie XH, Luo JM, et al. Targeted expression of miR-34a using the T-VISA System suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20(12):2326–34.PubMedCentralPubMedCrossRef

47.

Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592–603.PubMedCentralPubMedCrossRef

48.

Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722–30.PubMedCrossRef

Titel: Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer
verfasst von: Xiaoti Lin
Minqing Wu
Peng Liu
Fengqin Wei
Laisheng Li
Hailin Tang
Xinhua Xie
Xiaoping Liu
Lu Yang
Xiaoming Xie
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0868-9

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy

Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

Hodgkin’s lymphoma as Richter’s transformation in chronic lymphocytic leukemia

STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma

Thin melanoma and late recurrences: it is never too thin and never too late

Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie